Scribe Therapeutics Director Carl L. Gordon Receives Award of 14,725 Shares

What Happened
Carl L. Gordon, a director of Scribe Therapeutics (SCTX), received an award of 14,725 derivative shares on July 23, 2026. The award is reported at $0.00 per share and is a non‑cash equity grant (derivative). This is an equity compensation event rather than a market purchase or sale.

Key Details

• Transaction date: July 23, 2026; Form 4 filed July 27, 2026 (timely within two business days).
• Transaction type: Award/grant of derivative securities (code A); 14,725 shares reported at $0.00.
• Shares owned after transaction: Not disclosed in the excerpt of the filing. See full Form 4 for total holdings.
• Footnote: The award vests 1/3 on each of July 23, 2027, July 23, 2028 and July 23, 2029, subject to continued service.
• No indication of a simultaneous sale or cash exercise in this filing.

Context
This was a standard equity compensation grant to a director and does not represent an open‑market buy or sell. Because the award vests over three years and was reported as a derivative grant, it does not create immediate proceeds or indicate an immediate change in market exposure. Equity grants to directors are common as part of compensation and should be viewed as routine disclosure rather than a direct bullish or bearish trading signal.